Contents 4 dk okuma

Claim and source comparison

Comparison of a rat-study abstract, sections read of the MMFS-01 paper, the 2022 mixture abstract, methods/results/funding sections and correction of the 2026 Magtein paper, and NIH ODS safety information. Not a full clinical review.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Animal study

<strong>Synaptic plasticity in animal studies:</strong> Slutsky et al. (2010) reported increases in brain magnesium, hippocampal synaptic markers and memory measures in rats. These mechanistic findings do not demonstrate the same structural changes in humans or guarantee clinical benefit.

Synaptic markers and memory changes in rats do not establish increased human brain synaptic density or clinical superiority over other magnesium salts.

Source 1 · Abstract read

Human randomized controlled trial

Liu et al. (2016) randomized 51 adults aged 50–70 with cognitive complaints to MMFS-01 or placebo for 12 weeks; 44 completed the study. Overall cognitive composite scores and executive function showed positive findings, but superiority for sleep or anxiety could not be determined. The small sample and manufacturer funding warrant independent confirmation.

Results use 44 completers from 51 randomized people; Alzheimer and dementia patients were excluded. A single site, small sample and commercial author affiliations limit generalization; short-term tolerability does not establish safe medication combinations.

Source 2 · Full text read

Human randomized controlled trial

Zhang et al. (2022) compared 2 g/day of MagteinPS with placebo for 30 days in 109 adults. The formula contained magnesium L-threonate, phosphatidylserine and vitamins; memory-test score differences were reported.

A multi-ingredient product result cannot be attributed to magnesium L-threonate alone. A 2 g mixture is not 2 g of pure magnesium L-threonate or elemental magnesium; this trial did not separately test ingredient synergy.

Source 4 · Abstract read

Human randomized controlled trial

<strong>Lopresti and Smith (2026)</strong> compared 2 g/day Magtein with placebo for six weeks in 100 adults reporting dissatisfied sleep. Overall cognitive composite scores improved, with no difference on the Raven test. Some subjective sleep outcomes improved, but objective Oura ring sleep outcomes did not differ between groups. This manufacturer-funded trial does not establish guaranteed deep sleep or reversal of aging.

Threotech funded the study. Estimated cognitive age converts test scores to norms; it is not biological rejuvenation. The 2026-10-15 correction clarifies that analyses were two-tailed; authors state p-values and results were unchanged. Six-week findings do not establish chronic-insomnia treatment or long-term safety.

Source 5 · Source 8 · Full text read

Official safety summary

NIH ODS notes increased magnesium-toxicity risk with impaired kidney function. Magnesium supplements can reduce absorption of tetracycline/quinolone antibiotics and oral bisphosphonates. Follow the medicine leaflet and a doctor/pharmacist’s assessment.

This is general magnesium-supplement safety information, not L-threonate-specific interaction rates or a personal medication schedule. Normal kidney function or short-trial tolerability does not make every combination safe.

Source 6 · Official summary read

Our evidence and source methodology

Magnesium L-Threonate: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

What is Magnesium L-Threonate?

Magnesium L-threonate is a salt of magnesium and L-threonic acid. Foundational findings on higher brain magnesium and synaptic density come from animal studies. Some human cognition and sleep measures have improved; increased human brain synaptic density, prevention of aging and clinical superiority over other magnesium forms have not been demonstrated.

How should magnesium forms be compared?

Current human trials have not demonstrated better sleep or cognition from L-threonate through direct comparisons with other magnesium salts. Animal brain-magnesium findings do not establish a definitive human blood-brain barrier ranking or percentage increase.

Mechanism of Effect

Synaptic plasticity in animal studies: Slutsky et al. (2010) reported increases in brain magnesium, hippocampal synaptic markers and memory measures in rats. These mechanistic findings do not demonstrate the same structural changes in humans or guarantee clinical benefit.

Synaptic markers and memory changes in rats do not establish increased human brain synaptic density or clinical superiority over other magnesium salts.

Clinical Evidence

Liu et al. (2016) randomized 51 adults aged 50–70 with cognitive complaints to MMFS-01 or placebo for 12 weeks; 44 completed the study. Overall cognitive composite scores and executive function showed positive findings, but superiority for sleep or anxiety could not be determined. The small sample and manufacturer funding warrant independent confirmation.

Results use 44 completers from 51 randomized people; Alzheimer and dementia patients were excluded. A single site, small sample and commercial author affiliations limit generalization; short-term tolerability does not establish safe medication combinations.

Zhang et al. (2022) compared 2 g/day of MagteinPS with placebo for 30 days in 109 adults. The formula contained magnesium L-threonate, phosphatidylserine and vitamins; memory-test score differences were reported.

A multi-ingredient product result cannot be attributed to magnesium L-threonate alone. A 2 g mixture is not 2 g of pure magnesium L-threonate or elemental magnesium; this trial did not separately test ingredient synergy.

Lopresti and Smith (2026) compared 2 g/day Magtein with placebo for six weeks in 100 adults reporting dissatisfied sleep. Overall cognitive composite scores improved, with no difference on the Raven test. Some subjective sleep outcomes improved, but objective Oura ring sleep outcomes did not differ between groups. This manufacturer-funded trial does not establish guaranteed deep sleep or reversal of aging.

Threotech funded the study. Estimated cognitive age converts test scores to norms; it is not biological rejuvenation. The 2026-10-15 correction clarifies that analyses were two-tailed; authors state p-values and results were unchanged. Six-week findings do not establish chronic-insomnia treatment or long-term safety.

Dose information and research limits

Dose information and research limits

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

In the 2026 trial, 2 g of Magtein supplied 145 mg elemental magnesium. This quantity belongs to the study product and cannot be automatically transferred to different mixtures or products. Compound weight is not elemental magnesium weight; check the product label.

Safety and Side Effects

NIH ODS notes increased magnesium-toxicity risk with impaired kidney function. Magnesium supplements can reduce absorption of tetracycline/quinolone antibiotics and oral bisphosphonates. Follow the medicine leaflet and a doctor/pharmacist’s assessment.

This is general magnesium-supplement safety information, not L-threonate-specific interaction rates or a personal medication schedule. Normal kidney function or short-trial tolerability does not make every combination safe.

⚠ Important Notice

Kidney failure increases the risk of magnesium accumulation; consult a health professional before supplementation. Tetracycline and quinolone antibiotics should be taken at least 2 hours before or 4–6 hours after a magnesium supplement. Follow the medicine label and pharmacist advice; magnesium can bind these antibiotics and reduce absorption.

Related research and reading

These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.

Educational guides

Sources

  1. Slutsky I, et al. (2010). Enhancement of learning and memory by elevating brain magnesium. Neuron, 65(2), 165–177. PubMed · PMID 20152124
  2. Liu G, et al. (2016). Efficacy and Safety of MMFS-01, a Synapse Density Enhancer, for Treating Cognitive Impairment in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Alzheimer's Disease, 49(4), 971–990. PubMed · PMID 26519439
  3. Wang J, et al. (2013). Magnesium L-threonate prevents and restores memory deficits associated with neuropathic pain by inhibition of TNF-α. Pain Physician, 16(5), E563–E575. PubMed · PMID 24077207
  4. Zhang C, et al. (2022). A Magtein®, Magnesium L-Threonate, -Based Formula Improves Brain Cognitive Functions in Healthy Chinese Adults. Nutrients, 14(24), 5235. PubMed · PMID 36558392
  5. Lopresti AL, Smith SJ. (2026). The effects of magnesium L-threonate (Magtein®) on cognitive performance and sleep quality in adults: a randomised, double-blind, placebo-controlled trial. Frontiers in Nutrition, 12, 1729164. https://doi.org/10.3389/fnut.2025.1729164 PubMed · PMID 41601871
  6. NIH Office of Dietary Supplements. Magnesium: Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/ NIH Office of Dietary Supplements
  7. T.C. Tarım ve Orman Bakanlığı. Bir takviye edici gıdanın onaylı olup olmadığını nereden öğrenebiliriz? (2026). https://guvenilirgida.tarimorman.gov.tr/Haber/Detay/17314 T.C. Tarım ve Orman Bakanlığı
  8. Lopresti AL, Smith SJ. (2026). Correction: The effects of magnesium L-threonate (Magtein®) on cognitive performance and sleep quality in adults: a randomised, double-blind, placebo-controlled trial. Frontiers in Nutrition, 13, 2010644. PubMed · PMID 42959782

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions